title: Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
abstract: Chronic myeloid leukemia (CML) is characterized by Philadelphia chromosome (Ph) and BCR-ABL fusion genes. This study retrospectively analyzed 2381 CML patients with Ph chromosome confirmed by cytogenetics, Fluorescence in situ hybridization (FISH) or real-time quantitative polymerase chain reaction (Q-PCR). Among them, five CML patients without e13a2, e14a2 or e1a2 transcripts detected by Q-PCR were identified. DNA sequencing confirmed the fusion of BCR exon 14 and ABL exon 3. Case 1 reponded poorly to imatinib and achieved complete cytogenetic response (CCyR) after converting from imatinib to dasatinib. BCR-ABL transcripts were undetectable in cases after 2, 3 and 4 treated with imatinib after 6, 6 and 3 months, respectively, and in one patient who had undergone allogeneic hematopoietic stem cell transplantation after 4 months. Q-PCR may miss the detection of rare cases that are not covered by the primers used in Q-PCR, unless the proper primers are used.
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Xiaomin
authors.initials: X
authors.lastname: Gui
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.|b The Jinan Military General Hospital , Jinan , PR China.
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Jinlan
authors.initials: J
authors.lastname: Pan
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Huiying
authors.initials: H
authors.lastname: Qiu
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Jiannong
authors.initials: J
authors.lastname: Cen
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Yongquan
authors.initials: Y
authors.lastname: Xue
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Suning
authors.initials: S
authors.lastname: Chen
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Hongjie
authors.initials: H
authors.lastname: Shen
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Li
authors.initials: L
authors.lastname: Yao
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Yafang
authors.initials: Y
authors.lastname: Wu
authors.affiliation: a The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis , Suzhou , PR China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Chen
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005091:Exons; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D059785:Karyotype; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D019233:Retreatment; D014158:Transcription, Genetic; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl
keywords: Leukemia; TKIs; chronic; myeloid